AU2006322844A1 - Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof - Google Patents

Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof Download PDF

Info

Publication number
AU2006322844A1
AU2006322844A1 AU2006322844A AU2006322844A AU2006322844A1 AU 2006322844 A1 AU2006322844 A1 AU 2006322844A1 AU 2006322844 A AU2006322844 A AU 2006322844A AU 2006322844 A AU2006322844 A AU 2006322844A AU 2006322844 A1 AU2006322844 A1 AU 2006322844A1
Authority
AU
Australia
Prior art keywords
cancer
carcinoma
leukemia
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006322844A
Other languages
English (en)
Inventor
Eliezer Flescher
M Herzberg
Yoel Kashman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
SEPAL PHARMA Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
SEPAL PHARMA Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, SEPAL PHARMA Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of AU2006322844A1 publication Critical patent/AU2006322844A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/32—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/487—Saturated compounds containing a keto group being part of a ring containing hydroxy groups
    • C07C49/493—Saturated compounds containing a keto group being part of a ring containing hydroxy groups a keto group being part of a three- to five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/716—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2006322844A 2005-12-07 2006-12-07 Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof Abandoned AU2006322844A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74287505P 2005-12-07 2005-12-07
US60/742,875 2005-12-07
US77256706P 2006-02-13 2006-02-13
US60/772,567 2006-02-13
PCT/IL2006/001408 WO2007066336A2 (en) 2005-12-07 2006-12-07 Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2006322844A1 true AU2006322844A1 (en) 2007-06-14

Family

ID=38038558

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006322844A Abandoned AU2006322844A1 (en) 2005-12-07 2006-12-07 Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof

Country Status (9)

Country Link
US (1) US20090291904A1 (enExample)
EP (3) EP2402321A3 (enExample)
JP (2) JP5464856B2 (enExample)
AU (1) AU2006322844A1 (enExample)
BR (1) BRPI0619492A2 (enExample)
CA (1) CA2632653C (enExample)
DK (1) DK2617714T3 (enExample)
ES (1) ES2576980T3 (enExample)
WO (1) WO2007066336A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284274B2 (en) * 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
US20090291904A1 (en) * 2005-12-07 2009-11-26 Yoel Kashman Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
BRPI0714046A2 (pt) * 2006-07-10 2013-04-24 Univ Ramot mÉtodos de combinaÇço para tratar cÂncer
EP2121967A2 (en) 2007-03-15 2009-11-25 Ramot at Tel-Aviv University Ltd. Jasmonate based assays for identifying compounds that selectively inhibit mitochondrial bound hexokinases
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
CN103429234B (zh) * 2010-12-10 2016-10-05 布罗迪健康科学有限公司 茉莉酮酸酯治疗膀胱功能障碍的用途
BR112014006153A2 (pt) 2011-09-16 2020-12-01 Nanocare Technologies, Inc. composição farmacêutica, e, método para tratar um distúrbio
JP6081873B2 (ja) * 2013-06-24 2017-02-15 旭化成ファインケム株式会社 界面活性剤
WO2016109779A1 (en) 2014-12-31 2016-07-07 Nanocare Technologies, Inc. Jasmonate derivatives and compositions thereof
HUE054241T2 (hu) 2016-03-28 2021-08-30 Vidac Pharma Ltd Stabil gyógyszerkészítmények topikális beadásra és alkalmazásuk
AU2017311691B2 (en) 2016-08-18 2021-12-02 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
EP4464334A3 (en) 2016-11-07 2025-01-08 VIDAC Pharma Ltd. Use of compounds for treating hk2-expressing cancers
WO2018083704A1 (en) 2016-11-07 2018-05-11 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses
CN111556861A (zh) * 2018-01-07 2020-08-18 维达克制药有限公司 茉莉酸酯化合物的制备方法
CN113768911B (zh) * 2021-10-20 2023-10-27 郑州大学 Apobec3b抑制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981891A (en) * 1972-01-18 1976-09-21 Societe Anonyme Roure Bertrand Dupont Cyclopentanone derivatives, odoriferous compositions containing them and process of preparation thereof
FR2168147B1 (enExample) * 1972-01-18 1974-11-08 Roure Bertrand Dupont Sa
ZA747723B (en) * 1974-12-11 1976-11-24 Pfizer 11-desoxy-15-substituted-omega-pentanor prostaglandins
US4154949A (en) * 1974-12-11 1979-05-15 Pfizer Inc. 11-Desoxy-15-substituted-ω-pentanor prostaglandins
US3932389A (en) * 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
JPH06122653A (ja) * 1992-08-25 1994-05-06 Japan Tobacco Inc 飽和単環炭化水素化合物の製造方法およびその中間体
US5476945A (en) * 1992-11-17 1995-12-19 Fuji Photo Film Co., Ltd. Water-soluble methine derivatives of thiazole
US5637484A (en) * 1993-11-15 1997-06-10 Mitsui Petrochemical Industries, Ltd. Method of producing a taxane-type diterpene and a method of obtaining cultured cells which produce the taxane-type diterpene at a high rate
JP4041186B2 (ja) * 1997-07-09 2008-01-30 独立行政法人科学技術振興機構 ファイトアレキシン誘導剤
JPH11139908A (ja) * 1997-11-12 1999-05-25 Nippon Zeon Co Ltd ジャスモン酸系化合物を含有する寄生植物用発芽誘導剤
JPH11140022A (ja) * 1997-11-12 1999-05-25 Nippon Zeon Co Ltd ジャスモン酸系化合物とその製法
JP3815919B2 (ja) * 1999-05-26 2006-08-30 三井化学株式会社 タキサン型ジテルペンの製造方法
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
AU2002254342A1 (en) * 2001-03-23 2002-10-08 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
US6469061B1 (en) * 2001-04-04 2002-10-22 Ramot University Authority For Applied Research And Industrial Development Limited Jasmonate pharmaceutical composition for treatment of cancer
FR2825926A1 (fr) * 2001-06-14 2002-12-20 Sod Conseils Rech Applic Derives d'imidazoles modulant les canaux sodiques
FR2835525B1 (fr) * 2002-02-04 2006-02-10 Oreal Nouveaux composes, compositions les comprenant et leur utilisation pour favoriser la desquamation
US20030224024A1 (en) * 2002-02-04 2003-12-04 Jean-Luc Leveque Compositions comprising cyclopentane derivatives and their use
FR2835526B1 (fr) * 2002-02-04 2006-02-10 Oreal Nouveaux composes, compositions les comprenant et leur utilisation pour favoriser la desquamation
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
FR2843125B1 (fr) * 2002-08-02 2012-11-16 Coletica Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
WO2004091516A2 (en) * 2003-04-10 2004-10-28 Johns Hopkins University Methods for controlling the proliferation of cells
CN1193979C (zh) * 2003-06-23 2005-03-23 华东理工大学 茉莉酮酸酯衍生物及其在植物细胞中的应用
AU2004295206A1 (en) * 2003-12-02 2005-06-16 Ramot At Tel-Aviv University Ltd. Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof
US7026279B2 (en) * 2004-06-24 2006-04-11 International Flavors & Fragrances Inc. Use of 3-(methoxymethyl)-2-pentylcyclopenta derivatives in perfume compositions
US20090291904A1 (en) * 2005-12-07 2009-11-26 Yoel Kashman Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof

Also Published As

Publication number Publication date
EP2402321A3 (en) 2012-02-29
WO2007066336A3 (en) 2007-12-27
CA2632653C (en) 2014-11-04
EP2402321A2 (en) 2012-01-04
JP2013199483A (ja) 2013-10-03
EP1960364A2 (en) 2008-08-27
EP2617714B1 (en) 2016-03-23
ES2576980T3 (es) 2016-07-12
DK2617714T3 (da) 2016-06-27
WO2007066336A2 (en) 2007-06-14
CA2632653A1 (en) 2007-06-14
BRPI0619492A2 (pt) 2011-10-04
EP2617714A1 (en) 2013-07-24
JP5464856B2 (ja) 2014-04-09
JP2009519907A (ja) 2009-05-21
US20090291904A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
JP2013199483A (ja) ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法
US12162868B2 (en) Piperazine derivatives, pharmaceutical compositions and methods of use thereof
US7683211B2 (en) Jasmonate derivative compounds pharmaceutical compounds and methods of use thereof
WO2013138753A1 (en) Prodrugs of riluzole and their method of use
US8247439B2 (en) Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
US9284274B2 (en) Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
KR101599525B1 (ko) 알콕시페닐프로펜온 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
FI83780B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva (tio) flavener.
WO2019047824A1 (zh) 新型咪唑喹啉化合物及其制备方法和用途
IL229418A (en) Derivatives of gasmont, pharmaceutical preparations and their use
AU754086B2 (en) Alkyl ketones as potent anti-cancer agents
CN104529833B (zh) 取代的环丁烷羧酸类化合物及其用途
KR20230088718A (ko) 항종양 아스코르브산 에스테르
CN104402754B (zh) 作为神经氨酸酶抑制剂的化合物及其在药物中的应用
CN104496839B (zh) 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
HK1096382A (en) Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period